Fundraising FoxSiamab Therapeutics
Newton, US · Delaware corporation · 1 known investors
Find your way into Siamab Therapeutics
Sign up to see every warm intro you have to Siamab Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Siamab Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Siamab Therapeutics is a biopharmaceutical company developing therapeutic antibodies that target tumor-associated carbohydrate antigens (glycans) found on solid tumors such as ovarian, pancreatic, prostate, colon, and breast cancers. Its technology platform, based on glycobiology research licensed from UCSD, discovers highly specific anti-TACA antibodies intended to kill cancer cells and re-engage the immune system.
Founders & leadership
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.9M disclosed across 4 rounds · 2013–2018
▶$664.5KraisedNov 2018 · 21 investors · BiotechnologyRule 506(b)
- Jeffrey BehrensExecutive Officer, Director
- Gary PforzheimerDirector
- Brad CurleyDirector
- Peter KroonDirector
- Offering amount
- $2M
- Amount sold
- $664.5K
- First sale
- Oct 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.2MraisedMar 2016 · 64 investors · BiotechnologyRule 506(b)
- Jeffrey BehrensExecutive Officer, Director
- Robert MashalDirector
- Brad CurleyDirector
- Gary PforzheimerDirector
- Peter KroonDirector
- Offering amount
- $7M
- Amount sold
- $3.2M
- First sale
- Mar 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$527KraisedJul 2014 · 9 investors · BiotechnologyRule 506(b)
- Jeffrey BehrensExecutive Officer, Director
- Ajit VarkiDirector
- Brad CurleyDirector
- Sundar SubramaniamDirector
- Offering amount
- $1.5M
- Amount sold
- $527K
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedFeb 2014 · 43 investors · BiotechnologyRule 506(b)
- Brad CurleyDirector
- Ajit VarkiDirector
- Jeffrey BehrensExecutive Officer, Director
- Sundar SubramaniamExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Jul 2013
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Siamab Therapeutics do?
- Siamab Therapeutics is a biopharmaceutical company developing therapeutic antibodies that target tumor-associated carbohydrate antigens (glycans) found on solid tumors such as ovarian, pancreatic, prostate, colon, and breast cancers. Its technology platform, based on glycobiology research licensed from UCSD, discovers highly specific anti-TACA antibodies intended to kill cancer cells and re-engage the immune system.
- Who founded Siamab Therapeutics?
- Siamab Therapeutics was founded by Jeffrey Behrens, Sundar Subramaniam.
- Who are Siamab Therapeutics's investors?
- Siamab Therapeutics's investors include Boston Harbor Angels.
- How much funding has Siamab Therapeutics raised?
- Siamab Therapeutics has disclosed $6.9M raised across 4 rounds.
- Where is Siamab Therapeutics headquartered?
- Siamab Therapeutics is headquartered in Newton, US.